- Patients who have an inadequate response to current non-biologic DMARD therapy or the first anti-TNF agent (in monotherapy or in combination with MTX or other non-biologic DMARDs). Inadequate response to anti-TNF treatment is defined as not achieving an adequate response to treatment at 24 weeks or after a minimum period of 12 weeks therapy if permitted by the local guidance, defined as DAS28 score improvement of less than 1.2 or patients achieving a DAS28 score improvement of 1.2 but not acheiving low disease activity (current DAS28-ESR above 3.2)